HAS2-AS1 is a novel LH/hCG target gene regulating HAS2 expression and enhancing cumulus cells migration.


Journal

Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849

Informations de publication

Date de publication:
28 Feb 2019
Historique:
received: 17 12 2018
accepted: 18 02 2019
entrez: 2 3 2019
pubmed: 2 3 2019
medline: 2 5 2019
Statut: epublish

Résumé

The cumulus expansion process is one of the LH mediated ovulatory processes. Hyaluronan synthase 2 (HAS2) regulates the synthesis of hyaluronic acid, the main component of the cumulus expansion process. Recently, the lncRNA HAS2 antisense RNA 1 (HAS2-AS1) was identified in our global transcriptome RNA-sequencing of novel ovulation associated genes. The role of HAS2-AS1 in HAS2 regulation w.as studied previously with contradictive results in different models but not in the ovary. Taken together the induction of HAS2-AS1 and the important role of HAS2 in the cumulus expansion process, we hypothesize that HAS2-AS1 regulate HAS2 expression and function in the ovary. Therefore we undertook to study the expression, regulation, and possible functional role of HAS2-AS1 in the human ovary. HAS2-AS1, located within the HAS2 gene that was highly regulated in our library. We found that HAS2-AS1 express mainly in cumulus cells (CCs). Furthermore, HAS2-AS1 showed low expression in immature CCs and a significant increase expression in mature CCs. Functional studies reveal that inhibition of HAS2-AS1 by siRNA caused decrease expression of HAS2. Furthermore, inhibition of HAS2-AS1 by siRNA results in decrease migration of granulosa cells. Our results suggest that HAS2-AS1 is an LH/hCG target gene that plays a positive role in HAS2 expression and thus might play a role in regulating cumulus expansion and migration.

Sections du résumé

BACKGROUND BACKGROUND
The cumulus expansion process is one of the LH mediated ovulatory processes. Hyaluronan synthase 2 (HAS2) regulates the synthesis of hyaluronic acid, the main component of the cumulus expansion process. Recently, the lncRNA HAS2 antisense RNA 1 (HAS2-AS1) was identified in our global transcriptome RNA-sequencing of novel ovulation associated genes. The role of HAS2-AS1 in HAS2 regulation w.as studied previously with contradictive results in different models but not in the ovary. Taken together the induction of HAS2-AS1 and the important role of HAS2 in the cumulus expansion process, we hypothesize that HAS2-AS1 regulate HAS2 expression and function in the ovary. Therefore we undertook to study the expression, regulation, and possible functional role of HAS2-AS1 in the human ovary.
RESULTS RESULTS
HAS2-AS1, located within the HAS2 gene that was highly regulated in our library. We found that HAS2-AS1 express mainly in cumulus cells (CCs). Furthermore, HAS2-AS1 showed low expression in immature CCs and a significant increase expression in mature CCs. Functional studies reveal that inhibition of HAS2-AS1 by siRNA caused decrease expression of HAS2. Furthermore, inhibition of HAS2-AS1 by siRNA results in decrease migration of granulosa cells.
CONCLUSIONS CONCLUSIONS
Our results suggest that HAS2-AS1 is an LH/hCG target gene that plays a positive role in HAS2 expression and thus might play a role in regulating cumulus expansion and migration.

Identifiants

pubmed: 30819231
doi: 10.1186/s13048-019-0495-3
pii: 10.1186/s13048-019-0495-3
pmc: PMC6396505
doi:

Substances chimiques

Chorionic Gonadotropin 0
RNA, Long Noncoding 0
RNA, Messenger 0
RNA, Small Interfering 0
long noncoding RNA HAS2-AS1, human 0
HAS2 protein, human EC 2.4.1.212
Hyaluronan Synthases EC 2.4.1.212

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Subventions

Organisme : Ministry of Health, Israel
ID : 3-00000-7410
Organisme : Chaim Sheba Medical Center
ID : 05/2014

Références

Biol Reprod. 1999 Aug;61(2):436-43
pubmed: 10411524
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6
pubmed: 10468638
Endocrinology. 2001 Jan;142(1):437-45
pubmed: 11145608
J Biol Chem. 2001 Sep 21;276(38):35280-9
pubmed: 11463794
Oncogene. 2001 Nov 15;20(52):7588-96
pubmed: 11753637
J Biol Chem. 2002 Apr 19;277(16):13539-47
pubmed: 11805112
Reprod Domest Anim. 2002 Jun;37(3):144-51
pubmed: 12071888
Eur J Biochem. 2002 Sep;269(18):4551-8
pubmed: 12230567
Endocrinology. 2002 Nov;143(11):4375-84
pubmed: 12399434
Development. 2003 May;130(10):2253-61
pubmed: 12668637
Int Rev Cytol. 2004;235:251-91
pubmed: 15219785
Mol Cell Endocrinol. 2005 Apr 29;234(1-2):75-9
pubmed: 15836955
J Biol Chem. 2005 Jul 29;280(30):27513-22
pubmed: 15843373
Reprod Biomed Online. 2006 Oct;13(4):504-9
pubmed: 17007670
Hum Reprod Update. 2007 May-Jun;13(3):289-312
pubmed: 17242016
J Clin Invest. 2010 Apr;120(4):963-72
pubmed: 20364094
Prog Mol Subcell Biol. 2011;51:29-41
pubmed: 21287132
J Biol Chem. 2011 Jun 3;286(22):19523-32
pubmed: 21357421
Trends Plant Sci. 2012 Jan;17(1):16-21
pubmed: 22104407
Biol Reprod. 2012 Apr 27;86(4):125
pubmed: 22238281
DNA Cell Biol. 2012 Oct;31 Suppl 1:S34-41
pubmed: 22612272
Endocrinology. 2012 Aug;153(8):3949-59
pubmed: 22673225
Mol Hum Reprod. 2014 Aug;20(8):719-35
pubmed: 24770949
Mol Hum Reprod. 2014 Sep;20(9):844-9
pubmed: 24874553
J Biol Chem. 2014 Oct 17;289(42):28816-26
pubmed: 25183006
Development. 2014 Dec;141(23):4618-27
pubmed: 25359727
J Ovarian Res. 2014 Dec 11;7:113
pubmed: 25500128
Fertil Steril. 2016 Sep 1;106(3):653-659.e1
pubmed: 27341989
Endocrinology. 2017 Feb 1;158(2):402-409
pubmed: 27813675
Trends Genet. 2017 Oct;33(10):665-676
pubmed: 28870653
Sci Adv. 2017 Sep 27;3(9):eaao2110
pubmed: 28959731
Fiziol Zh. 2016;62(1):107-13
pubmed: 29537212

Auteurs

Yuval Yung (Y)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel. yuval.yung@sheba.gov.il.

Libby Ophir (L)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel.

Gil M Yerushalmi (GM)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel.

Micha Baum (M)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel.

Ariel Hourvitz (A)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel.

Ettie Maman (E)

IVF Unit and Reproduction Laboratory, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., 5262100, Tel Hashomer, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH